Society of Utah Medical Oncology

Welcome

Our primary mission is to promote the highest professional standards of oncology practice in the state of Utah; to study, research and exchange information, leading to improvement in the practice of hematology; to support and further oncology education; and to monitor and respond to appropriate legislative and regulatory concerns of the membership.

We encourage all oncology professionals to find out more about us and become a member of our growing community.

The Benefits of Membership

Become a member of the Society of Utah Medical Oncologists and enjoy these member only benefits:

  • Only professional organization that represents all hematology and oncology specialties and practices in Utah
  • Advocates on behalf of members on reimbursement and other issues
  • Provides a business meeting in the spring and a 1.5 day clinical meeting in the fall
  • Provides representation on legislative issues
  • Shares resources with other oncology-related organizations
  • Community outreach includes the University of Utah Oncology Interest Group for medical students
  • Acts as the institutional memory for the oncology community
  • Maintains a comprehensive database of member information
  • Collaborates with other state oncology societies, ASCO, COA, ASH and other entities as needed
  • Provides a comprehensive website
Join Today

 

 Dr. Xylina Gregg

Dr. Xylina Gregg, Oncologist at Utah Cancer Specialists, President Elect of SUMO
At the annual spring meeting,SUMO members voted unanimously to make Dr. Xylina Gregg the next president elect of SUMO. Dr. Gregg will replace the current president of SUMO, Dr. Howard Coleman and will continue his work of promoting SUMO’s mission. Dr. Gregg will take charge of leading and directing oncologists throughout the great state of Utah.

Click here for more

 

CMS' "Fail First" Step Therapy Policy Means Medicare Patients with Cancer Will Face More Dangerous Delays and Denials

Earlier this month, the Centers for Medicare & Medicaid Services (CMS) codified its decision to allow MA plans to use “fail first” step therapy for new starts of Part B drugs for cancer and other serious diseases. The Trump administration’s decision to finalize step therapy in MA plans means that Medicare patients with cancer will face nightmares of delays and denials while trying to access their physician-prescribed treatments

Click here for more

 

Learn more about the big changes to the ASH Scholar Award program.
More people are now eligible for the ASH Scholar Awards than ever before. The new Fellow to Faculty Scholar Award offers financial support to those preparing to compete for independent faculty-level positions in the next two to three years.

Click here for more.

Upcoming Events


2019 SUMO Spring Business Meeting 

Presentations now available in the members area.

 
2019 SUMO Fall Clinical Meeting
September 27 -28, 2019
Hyatt Centric Park City, 3551 N Escala Ct, Park City, UT 84098
Click here for more information

Don't miss out on the 2019 Best of ASCO Meetings

Two Days of Scientific Findings, Practice-Changing Discussion

The Best of ASCO Meetings condense the most cutting-edge science and education from the world’s premier oncology event, the ASCO Annual Meeting, into a two-day program. The abstracts chosen for presentation and discussion reflect the foremost research and strategies in oncology that will directly impact patient care.

Find out More here.

Economic Cost of Cancer in U.S. Tops $94B Annually According to a Study
State-by-state variations in cancer deaths suggest that effective cancer prevention and treatment could yield economic benefits, according to a study published in JAMA Oncology.

Click here for more.

Janssen provides discussion paper for 2020 Medicare Hospital Inpatient Prospective Payment System (IPPS) Proposed Rule.
The CMS fact sheet is available here.  In the FY 2020 IPPS Proposed Rule, CMS addresses how the agency proposes to pay for CAR T-cell therapy administered on an inpatient basis.

Click here for more

Denial Rates and Days to Pay for Cancer Drugs: Commercial Health Plan Report Card
Office-administered oncology drugs given in the community setting face stiff reimbursement challenges when billing commercial plans; while Medicare has emerged as the gold standard for both predictable payment and timeliness.

Click here for more.

 

COA Launches Major National Campaign to Stop PBM Abuses and Highlight Patient Horror Stories
COA recently launched a major national campaign to highlight the negative impact of pharmacy benefit managers (PBMs) on patients with cancer. The “PBM Abuses” campaign will ensure that PBM middlemen's abuse of patients with cancer is not lost in policy deliberations in Washington.

Click here for more

8 Medicare and Medicaid reforms that would have the biggest impact on federal spending

Click here for more